Tranexamic Acid
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Tranexamic Acid: From Abnormal Uterine Bleeding to Amenorrhea
One-Sentence Summary
Tranexamic acid is a well-known antifibrinolytic agent used to reduce excessive menstrual/surgical bleeding; it is not marketed in this jurisdiction and no official original-indication text is on file in this evidence pack. The TxGNN model predicts a possible link to Amenorrhea, but the only two supporting publications discuss bleeding suppression/prophylaxis in cancer patients — not amenorrhea treatment — and the mechanistic rationale itself flags a likely disease-entity mapping error between “abnormal uterine bleeding” and “amenorrhea.” With 0 clinical trials and 2 tangentially relevant reviews, this candidate does not currently meet the bar to advance past screening.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (drug is not marketed in this jurisdiction; no license records on file) |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.19% |
| Evidence Level | L4 |
| Market Status | ✗ Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is marked as a data gap in this evidence pack. Based on general pharmacology, tranexamic acid is a plasminogen activator inhibitor (antifibrinolytic): it blocks the conversion of plasminogen to plasmin, thereby reducing fibrin breakdown and decreasing bleeding. Its established clinical use is to reduce excessive bleeding — e.g., abnormal uterine bleeding (AUB)/menorrhagia, surgical bleeding, and trauma-related hemorrhage.
This creates a directional inconsistency with the predicted indication. Amenorrhea is the absence of menstrual bleeding, which is pharmacologically the opposite problem tranexamic acid is designed to address. The two literature sources retrieved for this candidate both discuss AUB pharmacotherapy and menstrual suppression/prophylaxis strategies in bleeding-risk cancer patients — a different clinical concept than TXA causing or treating amenorrhea. The evidence pack’s own rationale explicitly flags this as a likely knowledge-graph disease node confusion (AUB/menorrhagia vs. amenorrhea), rather than a genuine novel mechanistic hypothesis.
Given this, the prediction should be treated as a candidate for disease-entity verification before any further evaluation, not as a validated mechanistic hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21701432 | 2011 | Review | Menopause (New York, N.Y.) | Reviews pharmacological therapy for abnormal uterine bleeding (not amenorrhea); antifibrinolytics reduce excessive bleeding by 25–35%. |
| 39043214 | 2024 | Review | J Oncol Pharm Pract | Discusses menses prophylaxis and suppression strategies in pre-menopausal hematologic cancer patients with treatment-related cytopenias — a bleeding-risk-management context, not amenorrhea treatment. |
US Market Information
No license/authorization records are available — the drug is not marketed in this jurisdiction (total_licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA/local labeling data (warnings, contraindications, DDI) is marked as a Blocking data gap (DG001) in this evidence pack and could not be retrieved. This gap alone prevents progression to the S1 safety review stage.
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trial evidence exists for this indication, and the two available literature sources describe bleeding suppression/management contexts rather than amenorrhea treatment — the predicted indication is mechanistically inverted relative to tranexamic acid’s known antifibrinolytic action, suggesting a likely disease-entity mapping error in the knowledge graph.
- A Blocking safety data gap (DG001: local warnings/contraindications) independently prevents advancing to safety screening regardless of the indication question.
To proceed, the following is needed:
- Verify whether the TxGNN disease node “amenorrhea (disease)” was correctly mapped, or whether it should map to “abnormal uterine bleeding / menorrhagia” — this is a prerequisite before any further scientific review.
- Retrieve TFDA/local package insert warnings, contraindications, and DDI data (DG001).
- Retrieve confirmed MOA and original approved indication from DrugBank/regulatory sources (DG002).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.